More than 20 years after Congress established a national program to expand access to cord blood and bone marrow transplantation, federal lawmakers are considering another five years of investment in this important healthcare infrastructure.
In July 2026, the U.S. House of Representatives passed the Stem Cell Therapeutic and Research Reauthorization Act of 2025, H.R. 5160. The legislation would reauthorize and update the federal programs that support access to donated bone marrow and umbilical cord blood for transplantation through fiscal year 2031.
The legislation comes at an important time for the field. Cord blood has an established role in hematopoietic stem cell transplantation, while researchers continue to investigate additional applications for cord blood and cord blood-derived cells.
What H.R. 5160 Would Do
H.R. 5160 would continue federal support for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031.
According to the Congressional Budget Office, the legislation would authorize $33 million annually from fiscal years 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program and $23 million annually for the National Cord Blood Inventory. Together, those authorizations total approximately $280 million over five years. Authorization does not guarantee that the full amount will ultimately be appropriated.
These federal programs support the infrastructure used to help patients access unrelated donor bone marrow and cord blood stem cell transplants.
The legislation would also make changes to how the National Cord Blood Inventory is managed. Rather than maintaining a fixed inventory goal of at least 150,000 new high-quality cord blood units, H.R. 5160 would direct the Secretary of Health and Human Services to determine a sufficient supply and manage the size and composition of the inventory based on clinical utility, genetic diversity and efficient use of resources. The legislation also defines a high-quality cord blood unit as one meeting current industry standards and applicable FDA requirements.
An important distinction for families is that H.R. 5160 addresses the public donor system.
Public cord blood banks collect donated units that may be available to patients who need a suitable match. Cryo-Cell operates both a public bank and a private family bank. Its public bank has been a beneficiary of this federal funding in the past and understands its importance. Private family banks preserve a baby's cord blood so the family maintains access to those cells should a medically appropriate use arise.
Both involve cord blood preservation, but they serve different purposes.
More Than 20 Years of Federal Support
Federal support for this infrastructure is not new.
The original Stem Cell Therapeutic and Research Act was enacted in 2005, establishing the National Cord Blood Inventory and creating the federal framework for coordinating access to bone marrow and cord blood transplantation. Congress has continued its support for these programs through subsequent reauthorizations.
H.R. 5160 represents the next proposed five-year continuation of that federal commitment.
The House-passed version of H.R. 5160 was approved on July 20, 2026. The legislation was received in the Senate on July 21, where it was read twice and placed on the Senate Legislative Calendar.
There is also bipartisan activity in the Senate. S. 4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2026, was introduced by Sen. Jack Reed with Sens. Tim Scott, Tina Smith and James Lankford as original cosponsors. The Senate Committee on Health, Education, Labor, and Pensions subsequently reported the bill with an amendment in June.
H.R. 5160 has not yet become law. Further congressional action is required before legislation can be sent to the President.
Cord Blood's Established Role and Evolving Research
The consideration of H.R. 5160 also provides an opportunity to look at how the field of cord blood has evolved since the original legislation was enacted more than two decades ago.
Cord blood is an established source of hematopoietic stem cells. According to the U.S. Food and Drug Administration, cord blood can be used in hematopoietic stem cell transplantation for patients with certain disorders affecting the blood-forming system, including some blood cancers and inherited metabolic and immune system disorders.
At the same time, researchers continue to investigate other potential applications of cord blood and cord blood-derived cells.
One area of research involves the development of immune effector cells from cord blood for cellular therapies. This distinction is important. CAR-T therapies are established treatments for certain cancers, but research involving cord blood as starting material for manufacturing CAR-T and other immune effector cells represents an evolving area of cellular therapy research.
That research does not change the established indications for cord blood today. It does, however, demonstrate that scientists continue to study how cord blood and cord blood-derived cells may contribute to future advances in medicine.
Research Into Cerebral Palsy
Researchers are also studying cord blood in neurological conditions, including cerebral palsy.
A 2025 individual participant data meta-analysis published in Pediatrics evaluated umbilical cord blood treatment for children with cerebral palsy. The analysis found greater gains in gross motor function among children who received cord blood compared with controls at six and 12 months. Younger children and those with milder cerebral palsy showed greater benefit, and higher cell doses were associated with increased effect size.
The findings are encouraging, but they must be understood within the appropriate clinical context.
Cord blood treatment for cerebral palsy remains investigational and is not an FDA-approved use. The FDA states that currently approved cord blood stem cell products are blood-forming stem cell products used for disorders affecting the hematopoietic system and are not approved for other uses.
Additional research is needed to further understand which patients may benefit, appropriate dosing and treatment protocols, and the longer-term effects of treatment.
This distinction between established clinical uses and emerging research is particularly important when families are making decisions about newborn stem cell banking.
At Cryo-Cell, we believe families deserve clear information about both.
What Does This Mean for Families Considering Cord Blood Banking?
H.R. 5160 focuses exclusively on the public donor system, but the challenges it addresses are relevant to the broader conversation about cord blood banking.
Patients who need an allogeneic stem cell transplant may depend on the public registry to identify a suitable donor or cord blood unit. Finding that match can be more difficult for some patients, particularly those with less common HLA types or diverse ancestry. Maintaining a sufficiently large and genetically diverse public inventory is therefore an important part of ensuring access to transplantation.
These are distinct systems serving different needs. The public system provides an essential resource for patients searching for unrelated donor cells. Private banking allows families to preserve and maintain access to their own stored cord blood.
H.R. 5160 does not change that distinction. What it does demonstrate is continued federal investment in the nation’s cord blood and bone marrow transplant infrastructure, even as research into additional applications for cord blood and cord blood-derived cells continues to advance.
The Bottom Line
H.R. 5160 represents the latest chapter in more than two decades of federal investment in the nation’s cord blood and bone marrow transplant infrastructure. Its proposed reauthorization reflects the continued commitment to maintaining access to high-quality, genetically diverse cord blood units for patients who depend on the public donor system.
At the same time, the science of cord blood continues to evolve. Its role in hematopoietic stem cell transplantation is well established, while research continues to explore additional applications for cord blood and cord blood-derived cells.
Cryo-Cell has been part of this field since 1989, before the National Cord Blood Inventory was established and before many of today’s advances in cord blood science were possible. As the field continues to advance, our role remains the same: to preserve newborn stem cells to rigorous quality standards and provide families with clear, accurate information about the science, the research and what those developments may mean for the future.
Have questions about cord blood banking or recent developments in cord blood research? Talk to a Cryo-Cell specialist.
Sources: